Wells Fargo analyst Derek Archila raised the firm’s price target on Incyte (INCY) to $116 from $97 and keeps an Overweight rating on the shares. The firm believes shares should trade up on ‘989’s Phase 1 results in myelofibrosis that provided more evidence of its safety/efficacy, though recognized shares have priced in some of the move.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY: